6 drug(s) with this reaction
1,656 total reports
Cardiac Failure has been reported as an adverse reaction across 6 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,656 adverse event reports mention cardiac failure in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with cardiac failure, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have cardiac failure listed in their FDA adverse event reports, sorted by report count:
In addition to cardiac failure, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
6 drug(s) manufactured by Amgen Inc have cardiac failure listed in their FDA adverse event reports: DARBEPOETIN ALFA, FILGRASTIM, IVABRADINE, ROMOSOZUMAB-AQQG, EPOETIN ALFA, and others.
There are a combined 1,656 reports of cardiac failure across 6 Amgen Inc drug(s) in the FDA adverse event database.